Publications requirements

The journal «Oncology» (included in the The list of scientific professional editions of Ukraine (medicine, biology), the order of the Ministry of Education and Science of Ukraine of April 07, 2022 № 320) accepts articles that has not been published previously elsewhere and are not under consideration for publication in other publishing structures. Responsibility for the reliability of information and the originality of the submitted materials is of the authors. In the process of editing works, the editors reserve the right to change the style, but not the content of the articles. The papers executed without observance of requirements of edition are not registered. Primarily (with other things being equal) the work of the authors subscribers of the journal is published.

Refusal to publish may not be accompanied by an explanation of its cause and cannot be considered a negative conclusion about the scientific and practical value of the work. The works sent to the editorial staff are not returned. After publication, all copyrights belong to the editorial staff.

In papers that contain the results of clinical trials of medicinal products (including the use of registered drugs in another way in comparison with the registered dosage form, as well as for unregistered (new) indications), in the OBJECT AND METHODS OF RESEARCH data on the permit for clinical trials should be given in according to «Poryadok provedennya klinichnykh vyprobuvan likarskykh zasobiv ta ekspertyzy materialiv klinichnykh vyprobuvan» (order of the Ministry of Health of Ukraine from 23.09.2009, № 690).

The main characteristics of the oncoepidemiological process in Ukraine should be listed in accordance with the latest issue of the Bulletin of the National Cancer Register of Ukraine and are included in the REFERENCES section. The manuscript can be written in Ukrainian or English and should be accompanied by 6–8 keywords and a structured summary (with at least 1800 characters, including keywords) (necessarily in Ukrainian and English). The Summary should reflect the Aim, Object and Methods, Results, Conclusions. It is necessary to specify the full name of the organization(s) where the work was done, the names and initials of all authors, and also indicate the work place of each of them. The manuscript is presented in two copies, printed on one side of the sheet in two intervals with an indent from the left edge to 4 cm on A4 paper. Original and problematic work should be clearly structured and divided into sections with headings: INTRODUCTION, OBJECT AND METHODS OF RESEARCH, RESULTS AND DISCUSSION, CONCLUSIONS, REFERENCES. At the end of the article, the address, telephone number and e-mail of the author should also be sent to whom Correspondence will be sent.

The electronic manuscript is submitted in the text editor of Microsoft Word 97–2003 on electronic media or sent by e-mail: oncology_kiev@ukr.net.

Graphs and diagrams must be presented in Excel format. Photos are given in separate files in .tif or .jpg format with a resolution of 300 points per inch (the horizontal dimension is not less than 90 mm).

Tables and figures (links and notes to tables, signatures to figures placed directly below them) should be placed on separate pages and numbered with Arabic numerals in accordance with their mention in the text.

All physical quantities and units are given in SI; terms — according to anatomical and histological nomenclatures; diagnosis — according to the current International Classification of Diseases; medicines — by international names; test systems, reagents, equipment, devices — with the indication of the producer, the country.

References. The references are highlighted in the text in figures enclosed in square brackets. Numbering of references is carried out in alphabetical order or in the order of mention in the text. Unpublished data and personal messages are not listed in the list of literature. All references must be in English or in Latin transcription.

Examples of reference are listed below:

1. Poletto M, Legrand AJ, Fletcher SC, et al. p53 coordinates base excision repair to prevent genomic instability. Nucleic Acids Res 2016; 44 (7): 3165–75. doi: 10.1093/nar/gkw015.
2. Chekhun V, Naleskina L, Zadvornyi T, et al. Markers of bone tissue remodeling in carcinogenesis, tumor progression and metastasis: discourse of the possibilities of use in clinical oncology. Oncology 2022; 24 (3): 144–156. doi: 10.32471/oncology.2663-7928.t-24-3-2022-g.10813. (in Ukrainian).
3. Fedorenko ZP, Goulak LO, Gorokh YL, et al. Cancer in Ukraine, 2021–2022. Incidence, mortality, prevalence and other relevant statistics. Bulletin of the National Cancer Registry of Ukraine. Kyiv, 2023. 24. http://www.ncru.inf.ua/publications/BULL_24/index_e.htm
4. Al’Tshuler SA, Kozyrev BM. Electron paramagnetic resonance. New York: Acad Press, 2013. 382 p.
5. Domina EA, Druzyna MO, Ryabchenko NM. Individual human radiosensitivity. Kyiv: Logos, 2006. 126 p (in Ukrainian).
6. Glickson JD, Evanochko WT, Sakai TT. In vivo NMR studies of RIF-1 tumors. In: Magnetic Resonance in Cancer. Allen P, Boisvert DPJ, Lenth BC (eds). Toronto: Pergamon Press, 1986: 71–82.

ONCOLOGY
Scientific-practical journal
Published quarterly
Founded: March 1999